利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.059 秒)

    Ceramic structures for controlled release of drugs
    2.
    发明申请
    Ceramic structures for controlled release of drugs 审中-公开
    用于控释药物的陶瓷结构

    公开(公告)号：US20060165787A1

    公开(公告)日：2006-07-27

    申请号：US11181685

    申请日：2005-07-13

    申请人： Rudi Moerck ,  Bruce Sabacky ,  Jan Prochazka

    发明人： Rudi Moerck ,  Bruce Sabacky ,  Jan Prochazka

    IPC分类号： A61K9/22 ,  A61K9/14

    CPC分类号： A61K9/0053 ,  A61K9/143 ,  A61K9/145 ,  A61K9/1611

    摘要： The present invention provides compositions for controlled drug delivery, dosage forms, and processes for producing dosage forms. In a composition aspect of the present invention, a composition including a drug and a ceramic structure is provided. The ceramic structure has either a hollow portion wherein the drug is included in the hollow portion or is a collection of smaller particles bound together.

    摘要翻译： 本发明提供用于受控药物递送的组合物，剂型和用于生产剂型的方法。 在本发明的组合物方面，提供了包含药物和陶瓷结构的组合物。 陶瓷结构具有中空部分，其中药物包含在中空部分中，或者是结合在一起的较小颗粒的集合。

    Process for the recovery of malic acid
    4.
    发明授权
    Process for the recovery of malic acid 失效
    回收苹果酸的方法

    公开(公告)号：US4772749A

    公开(公告)日：1988-09-20

    申请号：US563983

    申请日：1983-12-21

    申请人： Michael Karrenbauer ,  Axel Kleemann ,  Wolfgang Leuchtenberger ,  Rudi Moerck

    发明人： Michael Karrenbauer ,  Axel Kleemann ,  Wolfgang Leuchtenberger ,  Rudi Moerck

    IPC分类号： C07C59/245 ,  C07C51/00 ,  C07C51/42 ,  C07C67/00 ,  C12P7/46

    CPC分类号： C12P7/46

    摘要： The reaction mixture obtained in the enzymatic reaction of fumaric acid to form L-malic acid contains the L-malic acid and unreacted fumaric acid as their salts. To recover pure solutions of L-malic acid the reaction mixture is treated at 50.degree. to 150.degree. C. with cation exchangers. The eluate after concentration to 30 to 80 weight % content of L-malic acid is filtered. The pure L-malic acid is recovered by evaporating the solutions, in a given case after treatment with activated carbon.

    摘要翻译： 在富马酸的酶促反应中获得的形成L-苹果酸的反应混合物含有L-苹果酸和未反应的富马酸作为其盐。 为了回收L-苹果酸的纯溶液，将反应混合物用阳离子交换剂在50-150℃下处理。 过滤浓缩至30〜80重量％L-苹果酸含量的洗脱液。 通过蒸发溶液来回收纯L-苹果酸，在给定情况下用活性炭处理后。

    Penetrating protectant
    7.
    发明授权
    Penetrating protectant 失效
    穿透保护剂

    公开(公告)号：US06335374B1

    公开(公告)日：2002-01-01

    申请号：US08320186

    申请日：1994-10-07

    申请人： Eeva-Liisa Kuusisto ,  Timothy Savage ,  Peter Schaeufele ,  Rudi Moerck

    发明人： Eeva-Liisa Kuusisto ,  Timothy Savage ,  Peter Schaeufele ,  Rudi Moerck

    IPC分类号： A61K4732

    CPC分类号： B27K3/34 ,  A01N47/12 ,  B27K3/15 ,  Y10S514/946 ,  A01N25/04 ,  A01N2300/00

    摘要： A penetrating concentrate containing a biocidal amount of a biocide uses a penetrating carrier vehicle containing an emulsifiable copolymer of a cyclic diene and a polymerizable, unsaturated glyceride. For biocides, such as iodopropargyl carbamate, which otherwise requires use of significant amounts of co-solvent to disperse, is directly soluble in the copolymer thereby eliminating or at least substantially reducing the need for co-solvents to assure stability of the biocide in the formulation. The concentrate also exhibits a low level of volatile organics.

    摘要翻译： 含有杀生物剂量的杀生物剂的渗透浓缩物使用含有环状二烯和可聚合的不饱和甘油酯的可乳化共聚物的穿透载体载体。 对于杀生物剂，如需要使用大量共溶剂分散的碘代炔丙基氨基甲酸酯，可直接溶于共聚物中，从而消除或至少显着降低对助溶剂的需求，以确保生物杀伤剂在制剂中的稳定性 。 浓缩物也表现出低水平的挥发性有机物。

    Phosphate binder with reduced pill burden
    9.
    发明申请
    Phosphate binder with reduced pill burden 审中-公开
    磷酸盐粘合剂减少药丸负担

    公开(公告)号：US20060134225A1

    公开(公告)日：2006-06-22

    申请号：US11250248

    申请日：2005-10-13

    申请人： Rudi Moerck ,  Alan Gotcher

    发明人： Rudi Moerck ,  Alan Gotcher

    IPC分类号： A61K33/24 ,  A61K31/724 ,  A61K31/717

    CPC分类号： A61K33/24 ,  A61K9/20 ,  A61K31/717 ,  A61K31/724 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention is generally directed to compositions and formulations that can be used for the treatment of diseases such as End Stage Renal Disease (“ESRD”) and Chronic Renal Insufficiency (“CRI”). Specifically, it is directed to lanthanum-based compounds that bind phosphate and that can be formulated to provide for a reduced pill burden relative to other phosphate binders. In a formulation aspect of the present invention, a formulation is provided the includes a lanthanum-based, phosphate binder. The formulation is typically characterized in that in may be swallowed without chewing. Formulations of the present invention, along with a lanthanum-based compound, may optionally include the following: mass diluting agents; binders; coatings; compression/encapsulation aids; disintegrants; lubricants; plasticizers; slip/anti-electrostatic agents; powder lubricants; and, sweeteners. Where the formulation is in the form of a tablet, it typically has a volume between 0.3 cm3 and 1.2 cm3, preferably between 0.35 cm3 and 0.50 cm3. Each tablet typically includes enough phosphate binder such that only 3 or less tablets need to be ingested each day for a patient suffering from ESRD.

    摘要翻译： 本发明一般涉及可用于治疗诸如终末期肾脏疾病（“ESRD”）和慢性肾功能不全（“CRI”）等疾病的组合物和制剂。 具体地，其涉及结合磷酸盐并且可以配制成相对于其它磷酸盐结合剂减少药丸负荷的镧基化合物。 在本发明的制剂方面，提供了包含镧基磷酸盐粘合剂的配方。 该制剂的特征在于其可以在不咀嚼的情况下吞咽。 本发明的制剂与镧基化合物一起可以任选地包括以下物质：大量稀释剂; 粘合剂 涂料; 压缩/封装辅助工具; 崩解剂 润滑油 增塑剂; 防滑剂/抗静电剂; 粉末润滑剂; 和甜味剂。 当制剂是片剂的形式时，其通常具有在0.3cm 3和1.2cm 3之间的体积，优选在0.35cm 3 / >和0.50cm 3。 每个片剂通常包括足够的磷酸盐粘合剂，使得每天仅需要摄取3个或更少的片剂用于患有ESRD的患者。